Ermium Therapeutics Overview
- Year Founded
-
2019
- Status
-
Out of Business
- Employees
-
9
- Latest Deal Type
-
Out of Business
Ermium Therapeutics General Information
Description
Developer of a biotechnology platform designed for the treatment of autoimmune inflammatory diseases. The company's platform engages in the research and development of the G protein-coupled receptor, which acts as a master regulator of inflammation via a novel mechanism of action, enabling physicians to effectively treat inflammatory diseases in patients.
Contact Information
Website
www.ermium.comCorporate Office
- 16 Boulevard Saint Germain
- 75005 Paris
- France
Corporate Office
- 16 Boulevard Saint Germain
- 75005 Paris
- France
Ermium Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 11-Jul-2024 | Completed | Out of Business | |||
| 3. Accelerator/Incubator | 04-Aug-2022 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 30-May-2022 | $13M | $13M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Ermium Therapeutics Comparisons
Industry
Financing
Details
Ermium Therapeutics Competitors (5)
One of Ermium Therapeutics’s 5 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Bioincept | Venture Capital-Backed | Cherry Hill, NJ | ||||
| Aurimi Therapeutics | Venture Capital-Backed | Woburn, MA | ||||
| Second Genome | Formerly VC-backed | Brisbane, CA | ||||
| Tessera Defense and Homeland Security | Formerly VC-backed | Dover, DE |
Ermium Therapeutics Patents
Ermium Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021349324-A1 | Cyclic isothiourea derivatives as cxcr4 modulators | Inactive | 28-Sep-2020 | ||
| AU-2021349324-A9 | Cyclic isothiourea derivatives as cxcr4 modulators | Inactive | 28-Sep-2020 | ||
| CA-3190549-A1 | Cyclic isothiourea derivatives as cxcr4 modulators | Pending | 28-Sep-2020 | ||
| EP-4217353-A1 | Cyclic isothiourea derivatives as cxcr4 modulators | Pending | 28-Sep-2020 | ||
| US-20240018125-A1 | Cyclic isothiourea derivatives as cxcr4 modulators | Inactive | 28-Sep-2020 | C07D403/12 |
Ermium Therapeutics Signals
Ermium Therapeutics FAQs
-
When was Ermium Therapeutics founded?
Ermium Therapeutics was founded in 2019.
-
Where is Ermium Therapeutics headquartered?
Ermium Therapeutics is headquartered in Paris, France.
-
What is the size of Ermium Therapeutics?
Ermium Therapeutics has 9 total employees.
-
What industry is Ermium Therapeutics in?
Ermium Therapeutics’s primary industry is Drug Discovery.
-
Is Ermium Therapeutics a private or public company?
Ermium Therapeutics is a Private company.
-
What is Ermium Therapeutics’s current revenue?
The current revenue for Ermium Therapeutics is .
-
How much funding has Ermium Therapeutics raised over time?
Ermium Therapeutics has raised $13M.
-
Who are Ermium Therapeutics’s competitors?
AnTolRx, Bioincept, Aurimi Therapeutics, Second Genome, and Tessera Defense and Homeland Security are competitors of Ermium Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process